Join the club for FREE to access the whole archive and other member benefits.

Sudhir Paul

Co-founder and Chief Science Officer at Covalent Bioscience and professor at the University of Nebraska

Dr. Sudhir Paul is a founder and scientist at Covalent Bioscience, a company developing Catalytic Immunotherapy/E-vaccine technologies.

Paul’s work as a Professor at the Universities of Nebraska and Texas has brought catabodies/E-vaccines from chemical curiosities to the verge of medical use. His research was funded continuously by the NIH, non-profit foundations and biotech companies since 1983. His early discovery patents were bought out (USD 21 MM) by Abgenix in 2001. He discovered harmful catabodies in autoimmune disease, progressing to devising our on-demand technology platform for generating catabodies and E-vaccines for disease treatment and prevention. He has authored ~200 original research articles and edited several books. Paul co-founded Covalent Bioscience. In 2018, he moved fulltime to Covalent to translate his know-how and inventions for medical benefits.

Visit website: https://covalentbioscience.com/about-us/

 Login to view link, or join the club to get full access to all resources and other benefits.

 Login to view link, or join the club to get full access to all resources and other benefits.

See also: Company Covalent Bioscience - Company focused on healthy aging and age-associated diseases using catalytic antibodies

Sudhir Paul is also referenced in the following:

Event
Ending Age-Related Diseases 2022
11-Aug-2022 to 14-Aug-2022

Virtual Conference for Rejuvenation Biotechnology and Life Extension organized by Lifespan Extension Advocacy Foundation